Auryxia (ferric citrate)

This policy covers Auryxia (ferric citrate) for treatment of hyperphosphatemia in adults with chronic kidney disease who are on dialysis and for management of iron‑deficiency anemia associated with CKD. Coverage is restricted to the listed indications, requires prior authorization and that the member meet all policy criteria — including documented prior trial, contraindication, or intolerance to both calcium acetate and sevelamer carbonate for the phosphate indication — with approval generally limited to the plan year or per clinical review.

"Hyperphosphatemia associated with Chronic Kidney Disease on Dialysis"

Sign up to see full coverage criteria, indications, and limitations.